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Upon growth factor stimulation or in some EGFR
mutant cancer cells, PKM2 translocates into the nu-
cleus to induce glycolysis and cell growth. Here, we
report that nuclear PKM2 binds directly to poly-
ADP ribose, and this PAR-binding capability is crit-
ical for its nuclear localization. Accordingly, PARP
inhibition prevents nuclear retention of PKM2 and
therefore suppresses cell proliferation and tumor
growth. In addition, we found that PAR level corre-
lates with nuclear localization of PKM2 in EGFR
mutant brain and lung cancers, suggesting that
PAR-dependent nuclear localization of PKM2 likely
contributes to tumor progression in EGFR mutant
glioblastoma and lung cancers. In addition, some
EGFR-inhibitor-resistant lung cancer cells are sensi-
tive to PARP inhibitors. Taken together, our data indi-
cate that suppression of PKM2 nuclear function by
PARP inhibitors represents a treatment strategy for
EGFR-inhibitor-resistant cancers.INTRODUCTION
Poly(ADP-robose) polymerase-1 (PARP1) or ADP-ribosyltrans-
ferase diphtheria toxin-like 1 (ARTD1) (Hottiger et al., 2010) is
the most abundant and the best understood member of the 17
PARP family proteins. PARP1 binds to both single-strand breaks
(SSBs) (Fisher et al., 2007; Okano et al., 2003) and double-strand
breaks (DSBs) (Ali et al., 2012) and participates in the recogni-
tion, excision, and repair of DNA damage (Kim et al., 2005).
The most extensively studied role of PARP1 is its involvement
in base excision repair (BER) (Dantzer et al., 1999; de Murcia
et al., 1997; Masson et al., 1998; Stro¨m et al., 2011; Trucco
et al., 1998). Moreover, suppression of PARP1/2 leads to syn-
thetic lethality in BRCA1/2-defecient tumors, indicating thatThis is an open access article undPARP1-dependent BER and BRCA-dependent homologous
repair pathway have overlapping and redundant functions in
DNA repair (Bryant et al., 2005; Farmer et al., 2005; Fong et al.,
2009; Rouleau et al., 2010). Recent studies have also pointed
to a broader utility of PARP inhibitors beyond hereditary
BRCA-deficient cancers (Gelmon et al., 2011; Inbar-Rozensal
et al., 2009; Telli, 2011).
Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme
that converts phosphoenolpyruvate (PEP) into pyruvate (Luo
and Semenza, 2012). Upregulation of PKM2 has been shown
recently to be an important feature of tumorigenesis (Hacker
et al., 1998; Mazurek et al., 2005). In tumor cells, PKM2 forms
a dimmer that is catalytically inactive as a glycolysis enzyme
(Mazurek et al., 2005) but provides advantage for tumor progres-
sion due to the Warburg effect (Christofk et al., 2008). Moreover,
recent studies have revealed that various stimuli and post-trans-
lational modifications including FGFR1-mediated Y105 phos-
phorylation (Hitosugi et al., 2009), ERK1/2-dependent S37 phos-
phorylation (Yang et al., 2012b), and P300-dependent K433
acetylation (Lv et al., 2013) trigger PKM2 translocation into nu-
cleus. Once in the nucleus, PKM2 acts as co-activator for several
transcription factors like HIF-1a (Luo et al., 2011) and b-catenin
(Yang et al., 2011). In addition, nuclear PKM2 also functions as
a protein kinase to phosphorylate STAT3 (Gao et al., 2012), His-
tone H3 (Yang et al., 2012a), and Bub3 (Jiang et al., 2014), all of
which contribute to promoting tumor growth or proliferation.
In this report, we demonstrated that PARP1-dependent poly-
ADP-ribose (PAR) is required for nuclear retention and nuclear
function of PKM2. PKM2 translocates into nucleus and binds
to PAR upon EGF stimulation. PARP inhibition, or the PKM2-C/
A mutant, which abolishes the PKM2/PAR interaction, sup-
presses the nuclear function of PKM2. In addition, PARP inhibi-
tion also diminishes the nuclear PKM2-dependent glycolysis and
tumor growth. Moreover, we showed that nuclear localization of
PKM2 correlates with PAR expression in EGFR mutant human
glioblastoma and lung cancer tissues. Interestingly, PARP inhibi-
tion leads to growth suppression of some EGFR mutant lung
cancer cells, which are resistant to EGFR inhibitor. These dataCell Reports 15, 843–856, April 26, 2016 ª2016 The Authors 843
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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together support an unexpected function of PARP inhibition in
tumor suppression and indicate that nuclear PKM2 may serve
as a promising biomarker for the further development of
PARP-inhibitor-based therapies.RESULTS
Nuclear PKM2 Binds to PAR In Vitro and In Vivo
TounderstandhowPoly-ADP-ribose (PAR) signaling participates
in various cellular processes, we used a biotin-PAR pull-down
coupled with a mass spectrometry approach to identify new
PAR-binding proteins. Mass spectrometry analysis revealed
not only several known PAR-binding DNA repair proteins (e.g.,
Ku70, XRCC1, Lig3, TOP1, and PNKP), but also PKM as a major
PAR-binding protein (Figure 1A).Weperformed in vitro PARbind-
ing assays using dot blot. The result showed that, just like the
positive control RNF146, both PKM1 and PKM2 bind directly to
PAR (Figure 1B). Reverse pull-down assays further confirmed
the direct interaction between PAR and PKM1 or PKM2 (Fig-
ure 1C). To further demonstrate the direct binding between
PKM2 and PAR, we performed the Biacore SPR assays and
showed that the association between PAR and PKM2 is direct
and specific (Figure S1A). To test the possibility that PKM2 itself
may be PARylated by PARP1, in vitro PARP1 PARylation assay
was performed, andHistone-H3was included as positive control
for PARP1 substrate. We showed that PARP1 could ribosylate it-
self andHistoneH3, but not PKM2 in vitro (Figure S1B), indicating
that PKM2 is not a substrate of PARP1.
We next explored whether PKM2 or PKM1 would associate
with PAR in vivo. As cellular PAR is dominantly localized in nu-
cleus and PKM2 could translocate from cytoplasm to nucleus
upon EGF stimulation (Yang et al., 2011), we speculated that
the PAR-binding activity of PKM2may promote its nuclear local-
ization. We thus used U87 human glioblastoma (GBM) cells,
which express wild-type EGFR with or without EGF treatment.
Immunoprecipitation (IP) with anti-PAR antibody followed by
western blotting with anti-PKM1 and anti-PKM2 antibodies re-
vealed that only the M2, but not M1, isoform of PKM binds to
PAR in vivo after EGF treatment (Figure 1D). Reciprocal co-IP us-
ing anti-PKM2 antibody confirmed this observation (Figure 1E).
In addition, cell fractionation co-IP and immunofluorescenceFigure 1. PKM2 Binds to PAR In Vitro and In Vivo
(A) PKMwas identified as a PAR binding protein. Biotin-PAR (from Trevigen) was u
The identified proteins and the number of peptides were listed.
(B) PKM1/2 binds PAR in vitro. The recombinant GST, GST-PKM1/2, and GST-RN
PAR was examined by dot blot using anti-PAR antibody.
(C) The interaction between Biotin-PAR and GST-PKM1/2 was examined by the
(D and E) EGF induced the PAR/PKM2 binding in vivo. U87/EGFRWT cells were s
Immunoprecipitation (IP) was carried out using anti-PAR antibody (D) or anti-PKM
(F) Nuclear PKM2 binds to PAR in vivo. Nuclear and cytoplasm fractions were pr
(G) PKM2 and PAR localized in the nucleus after EGF treatment. U87/EGFRWT c
were prepared for immunofluorescence staining.
(H and I) The PAR/PKM2 interactionwas abolished by PARP inhibitor. U87/EGFRW
(0.5uM) and then treated with EGF. Immunoprecipitation (IP) was carried out u
immunoblotting.
(J) Schematic diagram of the putative PAR-binding motif (C2H2 motif) in PKM2,
(K) The C2H2 motif of PKM2 is critical for PKM2/PAR binding. U87/EGFR WT cel
treated with EGF, and cell lysates were subjected to IP/dot-blot analysis.staining experiments indicated only PKM2, but not PKM1, could
translocate into the nucleus and bind to PAR upon EGF stimula-
tion (Figures 1F, 1G and S1C–S1F). We also used micro-irradia-
tion to show that PKM2 is indeed localized to where PAR is
induced, but only after EGF stimulation (Figure S1G). In U87/
EGFRvIII cells, which express the EGFRvIII mutant and display
constitutively active EGFR signaling, PKM2 partially localizes in
the nucleus and the nuclear PKM2 binds to PAR even without
EGF treatment (Figure 1F). Olaparib is a widely used PARP1/2-
specific inhibitor that suppresses PAR synthesis (Menear et al.,
2008). PKM2 could no longer bind to PAR following EGF treat-
ment when PAR level was significantly reduced upon olaparib
treatment (Figures 1H and 1I). Taken together, these data indi-
cate that EGF stimulation triggers PKM2 translocation into nu-
cleus and allows it to bind to PAR in the nucleus.
The above demonstrated in vitro and in vivo PAR-binding
activity of PKM2 prompted us to search for PAR-binding motif
in PKM2. There are several known PAR-binding motifs or do-
mains, which include the PAR-binding motif (PBM) (Gagne´
et al., 2008), macrodomain (Pehrson and Fried, 1992), PAR-bind-
ing zinc finger (PBZ) (Ahel et al., 2008), WWE domain (Aravind,
2001), BRCT and FHA domains (Li et al., 2013; Li and Yu,
2013), and PAR-binding regulatory motif (PbR) (Min et al.,
2013). We detected a putative C2H2 motif in PKM1/2 (Figures
1J and S1D), which is distinct from the PBZ C2H2 and the PbR
C2H2. This motif is highly conserved among various species (Fig-
ure 1J), indicating that it may serve as a PAR-bindingmotif, which
is important for PKM2 function. To determine whether the C2H2
motif of PKM2 is indeed critical for its binding to PAR, we gener-
ated an internal deletion mutant of PKM2 (PKM2D301-400),
which lacks the C2H2 motif, and two point mutants of PKM2
within the C2H2 motif (i.e., PKM2-C317/326A and PKM2-H379/
391A). Co-IP and dot-blot results showed that PKM2D301-400
and PKM2-C317/326A mutants failed to bind to PAR (Figure 1K),
indicating that this putative C2H2motif may be responsible for its
interaction with PAR. These data together suggest that PKM2 is a
PAR-binding protein.PAR Binding Is Required for PKM2 Nucleus Retention
PKM2 normally functions as a glycolic enzyme in the cytoplasm.
However, recent studies have demonstrated that PKM2 couldsed as the bait for whole-cell lysate pull-down andmass spectrometry analysis.
F146 (positive control) were incubated with Biotin-PAR, and protein-associated
reciprocal pull-down.
erum starved for 12 hr and then treated without or with EGF (100 ng/ml) for 6 hr.
2 antibody (E) and then subjected to immunoblotting.
epared, and IP/western analysis was conducted using indicated antibodies.
ells were serum starved and then treated without or with EGF (100 ng/ml). Cells
T cells were serum starved and treatedwithout or with PARP inhibitor olaparib
sing anti-PKM2 antibody (H) or anti-PAR antibody (I) and then subjected to
and key residues of the motif were highly conserved among various species.
ls that stably expressed the indicated constructs were serum starved and then
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Figure 2. PAR Binding Is Required for PKM2 Retention in Nucleus
(A and B) PARP inhibitor olaparib blocked EGF-induced nuclear localization of PKM2. U87/EGFRWT cells were serum starved for 12 hr and then pretreated with
U0126 (20 mM) or olaparib (0.5 mM) for 2 hr before treating with EGF (100 ng/ml) for 6 hr. Nuclear and cytoplasm fractions were prepared for immunoblotting (A),
and immunofluorescence analyses were carried out using indicated antibodies (B).
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translocate into nucleus and function as a protein kinase
involved in gene transcription and tumorigenesis (Gao et al.,
2012; Yang et al., 2012a). Since PKM2 binds to PAR in the nu-
cleus, we asked whether PAR would regulate nuclear localiza-
tion of PKM2. Cell fractionation and immunofluorescence stain-
ing experiments indicated that PARP inhibitor could abolish the
EGF-induced nuclear translocation of PKM2 (Figures 2A and
2B). In these experiments, we used MEK/ERK inhibitor U0126
as a positive control, which is known to block PKM2 transloca-
tion (Yang et al., 2012b). Moreover, all three PARP inhibitors
that we tested (i.e., olaparib, PJ34, and ABT-888) could inhibit
PKM2 nuclear translocation (Figure 2C). Olaparib inhibits both
PARP1 and PARP2 (Menear et al., 2008). We stably knocked
down PARP1 or PARP2 using small hairpin RNAs (shRNA) in
cells and found that only knockdown of PARP1, but not that of
PARP2, diminished EGF-induced nuclear localization of PKM2,
as PARP1 but not PARP2 is predominantly responsible for
PAR formation in the cell (Figure 2D). This may due to the fact
that the abundance of PARP1 is much higher than that of
PARP2 in vivo (Figure S2). Moreover, the PKM2-C317/326A
mutant, which could not bind to PAR, also failed to translocate
to nucleus following EGF treatment (Figure 2E). These data sug-
gest that PAR binding is critical for PKM2 nuclear localization.
PKM2 only associates with PAR in the nucleus, which ought
to happen after the translocation of PKM2 from cytoplasm. We
suspected that PAR binding should affect the nuclear retention,
but not nuclear translocation, of PKM2. To test this hypothesis,
we generated the PKM2-S37A mutant, which was resistant to
EGF-induced nuclear translocation (Yang et al., 2012b). This
PKM2mutant associated with PAR just like wild-type PKM2 (Fig-
ure S3A). While wild-type PKM2 displayed EGF-induced nuclear
translocation in U87/EGFR wild-type (WT) cells, both the PKM2-
S37A and the PKM2-C317/326A PAR-binding mutants failed to
do so (Figure 2F). Moreover, leptomycin B (LMB) treatment,
which abolishes the export of nuclear proteins, led to the nuclear
localization of the PKM2-C317/326A mutant, but not the PKM2-
S37A mutant after EGF treatment (Figure 2F). These observa-
tions indicate that, while the S37 phosphorylation is important
for PKM2 nuclear translocation as previously reported (Yang
et al., 2012b), the PAR-binding activity of PKM2 is critical for
PKM2 nuclear retention.
PAR Regulates Nuclear Functions of PKM2
Cytoplasmic PKM2 normally function as a glycolysis enzyme,
while nuclear PKM2 was reported as a coactivator for HIF-1a
(Luo et al., 2011) and b-catenin (Yang et al., 2011). It was previ-
ously reported that the dimer and tetramer forms of PKM2(C) Three different PARP inhibitors blocked PKM2 nuclear localization. U87/EG
(0.5 mM), PJ34 (2.5 mM), and ABT-888 (1 mM) for 2 hr before treating with EGF (100
immunoblotting.
(D) EGF-induced nuclear localization of PKM2 requires PARP1. PARP1 or PARP
treated without or with EGF. Cell fractions were subjected to immunoblotting an
(E) EGF fails to trigger the nuclear localization of PKM2-C/A mutant. U87/EGFRW
starved and treated without or with EGF. Cell fractions were prepared and analy
(F) PAR binding is required for PKM2 nuclear retention. U87/EGFRWT cells stably
starved and then treated with EGF, LMB (2 ng/ml for 1 hr), or combination of t
antibodies.coexist in proliferation cells (Mazurek et al., 2005), the tetramer
form of PKM2 was responsible of pyruvate kinase activity in
the cytosol, and the dimer form was responsible for PKM2 nu-
clear function (Gao et al., 2012). Since PAR binds to PKM2 in
the nucleus, we suspected that PAR binding would be required
for PKM2 functions in the nucleus, but not in the cytosol. We
therefore generated bacteria expressed and purified wild-type
PKM2, PKM2-C317/326A, PKM2-S37A, and PKM2-R399E pro-
teins and performed in vitro pyruvate kinase assays. The PKM2-
R399E mutant was reported to promote the tetramer to dimer
transition and thus reduce the pyruvate kinase activity of
PKM2 (Gao et al., 2012), and the PKM2-S37A mutant was
thought to have no effect on PKM2 pyruvate kinase activity
(Yang et al., 2012b). In agreement with these early reports, we
showed that both the PAR-binding-defective PKM2-C317/
326Amutant and the PKM2-S37Amutant exhibited similar pyru-
vate kinase activity as wild-type PKM2, while the PKM2-R399E
mutant displayed reduced pyruvate kinase activity (Figures 3A
and S3B), indicating that PAR binding is not required for PKM2
pyruvate kinase activity.
We further examined the effect of PAR on PKM2 nuclear func-
tions in vivo. Since nuclear PKM2 is required for expression of
several glycolysis genes c-Myc, GLUT, and LDHA (Luo et al.,
2011; Yang et al., 2011, 2012b). Indeed, PKM2 depletion and
rescue experiments demonstrated that olaparib suppressed
expression of c-Myc, GLUT, and LDHA (Figure 3B) and thus
reduced lactate production and glucose uptake in PKM2-depen-
dent manner (Figures 3D and 3E). Consistently, the PKM2-C317/
326A mutant, which could not bind to PAR, failed to reverse the
decrease of glycolysis induced by PKM2 knockdown (Figures
3C–3E). These results demonstrated that PAR binding is re-
quired for nuclear PKM2-induced glycolysis.
PAR Binding Promotes Nuclear PKM2-Induced Cell
Proliferation and Tumor Growth
Nuclear PKM2was reported to be involved in cell proliferation and
theWarburg effect (Gao et al., 2012; Yang et al., 2012b), which led
us todeterminewhetherPARwould affect cell proliferation. To this
end, we first checked the effect of PARP inhibitor on the prolifera-
tion of U87/EGFR WT and U87/EGFRvIII cells. In U87/EGFR WT
cells, PARP inhibitor olaparib only suppressed cell proliferation
when these cells were stimulated with EGF, whereas in U87/
EGFRvIII cells olaparib reduced cell proliferation even in the
absence of EGF since EGF signaling is constitutively activated in
these cells (Figure 4A). Correspondingly, we noticed that PKM2
only displayed nuclear localization in U87/EGFR WT cells upon
EGF stimulation, while U87/EGFRvIII cells showed constitutiveFR WT cells were serum starved for 12 hr and then pretreated with olaparib
ng/ml) for 6 hr. Nuclear and cytoplasm fractions were prepared and analyzed by
2 stable knockdown and control U87/EGFR WT cells were serum starved and
alysis using indicated antibodies.
T cells stably expressing wild-type PKM2 or the PKM2-C/A mutant were serum
zed by western blotting.
expressed S-Flag-SBP (SFB)-tagged PKM2 or PKM2-C317/326A were serum
he two, and immunofluorescence analyses were carried out using indicated
Cell Reports 15, 843–856, April 26, 2016 847
CA
U87 wt
  + - -
- -
  + -
  + -   +   +
olaparib
Flag-PKM2
sh-PKM2
EGF
  + 
  +   + 
  +   + 
- -
-
- -   + 
 + 
  + - -   + 
  + 
IB:
Tubulin
LDHA
GLUT1
c-myc
Flag
PKM2
PAR
U87 wt
-
-
Flag-PKM2-wt
EGF
  +   + 
- -
  +  + 
  + -   + - -  + -   + 
-   +   + sh-PKM2
-
IB:
Tubulin
LDHA
GLUT1
c-myc
Flag
PKM2
B
LDHA
GLUT1
c-myc
actin
R
T-
P
C
R
LDHA
GLUT1
c-myc
actin
R
T-
P
C
R
La
ct
at
e 
pr
od
uc
tio
n
   
 (m
m
ol
/1
0 
  c
el
ls
)
0.0
0.1
0.2
0.3
0.4
4
shv shM2 shM2
 +M2
p=1.2×10-3
p=0.15
p=1.8×10-4
shv shM2  shM2
+wtM2
 shM2
+mtM2
La
ct
at
e 
pr
od
uc
tio
n
   
 (m
m
ol
/1
0 
  c
el
ls
)
0.0
0.1
0.2
0.3
0.4
4
p=3.1×10-4
p=3.7×10-4
p=0.09
D
shv shM2 shM2
 +M2
DMSO 
olaparib(0.5μM)
DMSO 
olaparib(0.5μM)
p=8.4×10-4 p=2.5×10-3
p=0.13
0
10
20
30
40
2-
N
B
D
G
 u
pt
ak
e 
(%
)
50
60
E
0
10
20
30
40
2-
N
B
D
G
 u
pt
ak
e 
(%
)
50
60
70
shv shM2  shM2
+wtM2
 shM2
+mtM2
p=6.9×10-4
p=0.29p=9.8×10-4
0
20
40
60
80
100
120
R
el
at
iv
e 
py
ru
va
te
 
ki
na
se
 a
ct
iv
ity
GST M2-
 wt
  M2-
C317
/326A
 M2-
S37A
  M2-
R399E
  +   + - -
-Flag-PKM2-
C317/326A
- - -   +   + - -
Figure 3. PAR Regulates Nuclear Functions
of PKM2
(A) The activity of GST, GST-PKM2, andmutants of
PKM2 toward PEP was measured using in vitro
pyruvate kinase assays.
(B) Effect of olaparib on glycolysis gene expression
requires PKM2. U87/EGFR WT cells with stable
PKM2 knockdown or reintroduction of PKM2 were
serum starved and treatedwithout or with EGF and
olaparib. Cells were collected and examined by
western blotting and RT-PCR as indicated.
(C) EGF fails to trigger glycolysis gene upregulation
in PKM2- C317/326A cells. U87/EGFR WT cells
with stable PKM2 knockdown followed by re-
introduction of wild-type PKM2 or PKM2- C317/
326A mutant were serum starved and treated
without or with EGF. Cells were collected and
examined by western blotting and RT-PCR for the
detection of c-Myc and glycolysis genes such as
GLUT1 and LDHA.
(D and E) Lactate production (D) and glucose
uptake (E) were measured in the indicated U87/
EGFRvIII cells; wtM2 is identical to wild-type
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mutant.
Data are means ± SD (n = 3 independent experi-
ments).
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nuclear localization of PKM2 (Figure 4A), implying that the effect of
PARP inhibitor on cell proliferation may depend on PKM2 nuclear
localization. To test this possibility, we established PKM2 knock-
down U87/EGFRvIII cells and reintroduced wild-type PKM2 or
PKM2-C317/326A mutant in these knockdown cells. We found
that olaparib did not significantly reduce cell proliferation in
PKM2 knockdown cells, while reintroduction of shRNA-resistant
PKM2 restored olaparib-induced growth inhibition (Figure 4B).
Moreover, similar to olaparib treatment, PKM2 knockdown sup-
pressed proliferation of U87/EGFRvIII cells, whereas re-expres-
sion of wild-type PKM2, but not the PKM2-C317/326A mutant,
rescued this proliferation defect (Figure 4B). These results were
confirmedbybromodeoxyuridine (BrdU) incorporation (Figure 4C)
and colony formation assays (Figure 4D).
In addition, we tested the effect of PARP inhibition on PKM2-
dependent tumor growth using xenograft models. We showed
that PARP inhibitor olaparib-treated tumors displayed smaller
tumor volume and weight compared to vehicle-treated tumors
(Figures 4E and 4F). However, this inhibitor effect of olaparib
on tumor growth was dampened when we used PKM2 knock-
downU87/EGFRvIII cells (Figures 4E and 4F). Moreover, mice in-
jected with PKM2 knockdown U87/EGFRvIII cells showed signif-
icantly reduced tumor growth, while this reduction was rescued
by reintroduction of wild-type PKM2, but not the PKM2-C317/
326A mutant (Figures 4G and 4H). Taken together, these results
demonstrated that PAR binding is required for nuclear PKM2-
induced cell proliferation and tumor growth.
PARP Inhibitor Suppresses Growth of EGFR Mutant
Lung Cancer Cells by Targeting Nuclear PKM2
Somatic mutations of EGFR play a critical role in tumor progres-
sion and therapeutic response in human lung cancers (Paez
et al., 2004). We showed above that PARP inhibitor suppressed
nuclear PKM2-induced cell proliferation upon EGF stimulation or
activation. Thus, we decided to test whether any of the EGFR
mutant lung cancer cells would be sensitive to PARP inhibition.
We used three lung cancer cell lines with wild-type EGFR (i.e.,
A549, H358, and H460) and ten EGFR mutant lung cancer cell
lines (i.e., H1650, HCC827, HCC2279, HCC2935, HCC4006,
PC9, H820, H3255, HCC4011, and H1975) (Figure S4A). In
EGFR wild-type A549, H358, and H460 cells and EGFR mutant
HCC827, HCC2279, H820, H3255, and HCC40111 cells, PKM2
mainly localized in the cytoplasm, and these cells were resistant
to PARP inhibitor olaparib (Figures 5A and S4B; Table S1),
whereas, in EGFR mutant H1650, H1975, PC9, HCC2935, andFigure 4. PAR Binding Promotes PKM2-Induced Cell Proliferation and
(A) PARP inhibitor olaparib suppresses cell proliferation in U87 cells. U87/EGFR
eration was determined. Data are means ± SD (n = 3 independent experiments),
(B) The indicated PKM2 stable knockdown cells and cells with reintroduction o
without or with olaparib, and cell proliferation was measured at day 6 (n = 3).
(C) The BrdU staining of indicated U87/EGFRvIII cells were performed, and the p
dependent experiments).
(D) The indicated U87/EGFRvIII cells were tested in colony formation assay. Viab
(E and F) Tumor volume (E) and weight (F) of mice with subcutaneous injection o
presented (n = 5 mice, mean ± SD).
(G and H) Tumor volume (G) and weight (H) of mice with subcutaneous injection o
presented (n = 6 mice, mean ± SD); wtM2 is identical to wild-type PKM2, and m
850 Cell Reports 15, 843–856, April 26, 2016HCC4006 cells, PKM2 localized in the nucleus, and these cells
were sensitive to olaparib treatment (Figures 5A and S4C; Table
S1). We further established H1650, H1975, and PC9 derivative
cell lines with stable PKM2 knockdown and showed that deple-
tion of PKM2 converted these two cell lines from olaparib sensi-
tive to olaparib resistant (Figures 5B and S5A). These results
were confirmed by colony formation assays (Figure 5C), indi-
cating that nuclear PKM2 may be a marker for cancer cells
that are sensitive to PARP inhibition.
H1975 is a non-small cell lung cancer cell line that was re-
ported to contain L858R/T790M EGFR mutations, and H1650
had a deletion on exon 19 of EGFR, and they were highly resis-
tant to EGFR inhibitor gefitinib (Pao et al., 2005). We used
EGFR inhibitor gefitinib and PARP inhibitor olaparib and found
that as expected A549 cells were resistant to single or combina-
tion treatment of gefitinib/olaparib (Figures 5D, 5E, and S5B).
However, PC9, HCC2935, and HCC4006 cells were very sensi-
tive to gefitinib and combination of these two inhibitors showed
at least additive effect (Figures 5D, 5E, and S4C; Table S1). Inter-
estingly, H1650 and H1975 cells were resistant to gefitinib, but
sensitive to olaparib, and the combination of these two inhibitors
led to significant growth inhibition (Figures 5D, 5E, and S5B; Ta-
ble S1). These data suggest that, by targeting nuclear functions
of PKM2, PARP inhibitors may be used to treat EGFR mutant
lung cancers, especially some of the EGFR-inhibitor-resistant
cancers, which provides a way to overcome therapeutic resis-
tance for EGFR mutant cancers.
Nuclear Localization of PKM2 Is Associated with PAR
Expression in EGFR Mutant Tumors
Our results so far have indicated that inhibition of PAR reduces
growth of EGFR mutant cancers by suppressing PKM2 nuclear
localization and PKM2 nuclear functions. To determine the
clinical relevance of PKM2 regulation by PAR in human cancers,
we first validated that the anti-PKM2, PAR, and p-EGFR anti-
bodies are suitable for immunohistochemistry (IHC) staining (Fig-
ure S6A). We then determined the expression of p-EGFR, PKM2,
and PAR in patient-derived glioblastoma and lung carcinoma
tissue samples (Figure 6A). We found that p-EGFR and PKM2
expressions were upregulated in glioblastoma (20% positive
p-EGFR staining in normal cerebrum versus 61.4% positive
p-EGFR staining in glioblastoma, and 40% positive PKM2 stain-
ing in normal cerebrum versus 82.9% positive PKM2 staining
in glioblastoma, respectively) and lung cancers (10% positive
p-EGFR staining in normal lung tissue versus 42.7% positiveTumor Growth
WT and U87/EGFRvIII cells were treated with EGF or olaparib, and cell prolif-
and immunofluorescence analyses were carried out using PKM2 antibody.
f wild-type PKM2 or PKM2-C317/326A mutant in U87/EGFRvIII were treated
ercentages of positive cells are summarized. Data are means ± SD (n = 3 in-
le colonies after 12 days were counted and analyzed (n = 4).
f 5 3 106 indicated U87/EGFRvIII cells with vehicle or olaparib treatment were
f 5 3 106 shv, shM2, shM2+wtM2, and shM2+mtM2 U87/EGFRvIII cells were
tM2 is identical to PKM2-C317/326A mutant.
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p-EGFR staining in lung carcinoma, and 40% positive PKM2
staining in normal lung tissue versus 88.2% positive PKM2 stain-
ing in lung carcinoma), while there was no significant change in
PAR expression in normal tissue versus in tumor tissue in both
glioblastoma and lung carcinoma tissue microarray samples
(Figure 6B). Moreover, in all PKM2 positive samples, nuclear
PKM2 expression was upregulated (none in normal cerebrum
versus 60.3% in glioblastoma, and none in normal lung tissue
versus 40.2% in lung cancer) (Figure 6B).
Interestingly, PKM2 nuclear localization correlated with EGFR
activation (Figure 6D), which is consistent with the previous
study (Yang et al., 2012a), but PAR levels shown no correlation
with EGFR activation (Figure S6B). Notably, nuclear expression
of PKM2 correlated with PAR only in p-EGFR positive tumor
samples (Figures 6C, 6D, and S6B), indicating that PAR might
be required for nuclear localization of PKM2 when EGF signal
was activated. These results supported a role for PAR-depen-
dent nuclear function of PKM2 in glioblastoma and lung carci-
noma and partially explained why only about 40%–60% of
EGFR mutant tumors showed nuclear PKM2.
DISCUSSION
In this study, we identified nuclear PKM2 as a target of PARP
inhibition. Our results demonstrated that PKM2 contains a
conserved PAR-binding C2H2 motif, which is similar to PBZ
(Ahel et al., 2008) and PbR (Min et al., 2013) C2H2 motif. Upon
growth stimuli, cytoplasmic PKM2 translocates into nucleus
and binds to PAR through this C2H2 motif. We showed that
the PKM2/PAR interaction is required for PKM2 nuclear retention
and functions. Moreover, PAR level positively correlates with
PKM2 nuclear expression in EGFR mutant patient samples,
and cancers contain nuclear PKM2 show significant sensitivity
to PARP inhibition. These data not only revealed a mechanism
of PAR-dependent regulation of nuclear PKM2, but also high-
lighted the potential application of PARP inhibitors in cancer
therapy beyond BRCA mutant cancers.
Many PAR-binding domains and PAR-binding proteins have
been identified recently and shown to act as importantmediators
involved in various signaling pathways and cellular processes (Li
and Chen, 2014). The PAR-binding motif (PBM) (Gagne´ et al.,
2008)-containing protein p53 and p21 are involved in cell-cycle
control and proliferation (Fahrer et al., 2007; Pleschke et al.,
2000), while the binding of PAR to the PBM of Ku70 and
XRCC1 is believed to regulate cellular response to DNA damage
(Pleschke et al., 2000). In addition, the macrodomain-containing
proteins macroH2A1 and macroH2A2 function in transcription
regulation (Changolkar et al., 2007; Costanzi and Pehrson,
2001). The PBZ motifs of APLF and CHFR interact with PAR toFigure 5. PARP Inhibitor Suppresses Growth of EGFR Mutant Lung Ca
(A) A549, PC9, H1650, and H1975 cells were treated without or with olaparib (0
dependent experiments). Immunofluorescence analyses were carried out using P
(B) PC9, H1650, and H1975 with PKM2 stable knockdown or control cells were
proliferation. Data are means ± SD (n = 3 independent experiments).
(C) The indicated cells were treatedwithout or with olaparib and tested in colony fo
(D) The A549, PC-9, H1650, and H1975 cells were treated with gefitinib or olapa
(E) The indicated cells were treatedwith gefitinib or olaparib and tested in colony fo
852 Cell Reports 15, 843–856, April 26, 2016control DNA damage response and mitotic checkpoint, respec-
tively (Ahel et al., 2008). TheWWEdomain of RNF146 also recog-
nizes PAR and participates in RNF146- and PAR-mediated
degradation of Axin (Huang et al., 2009), 3BP2 (Levaot et al.,
2011), and PTEN (Li et al., 2015a). Here, we identified a putative
PAR-binding C2H2 motif in PKM2 and demonstrated that PAR
binding is critical for the nuclear retention and nuclear functions
of PKM2. This study further expands our understanding of PAR
signaling in diverse cellular processes.
The M2 isoform of pyruvate kinase (PKM2) contributes to
tumorigenesis and the Warburg effect (Christofk et al., 2008;
Lim et al., 2012). Cancers often evolve complex regulation of
PKM2 tomeet their needs for energy and cellular building blocks.
For examples, HIF-1 and c-Myc regulate transcription and
splicing of PKM2 (David et al., 2010; Luo et al., 2011), while
v-Src and FGFR1 (fibroblast growth factor receptor type1)
control the tetramer-to-dimer transition of PKM2 via phosphory-
lating PKM2 (Hitosugi et al., 2009; Presek et al., 1988). As a
matter of fact, various post-translational modifications are
known to occur on and regulate PKM2. These modifications on
PKM2 include its K305 acetylation (Lv et al., 2011), K433 acety-
lation (Lv et al., 2013), C358 oxidation (Anastasiou et al., 2011),
P403/408 hydroxylation (Luo et al., 2011), and S37 phosphoryla-
tion (Yang et al., 2012b). In our study, we demonstrated a mech-
anism for PKM2 regulation via PAR signaling, which is critical for
PKM2 nuclear retention and nuclear function.
While the glycolytic function of PKM2 in cytosol is well studied,
the nuclear functions of PKM2 as coactivator for HIF-1a (Luo
et al., 2011) and b-catenin (Yang et al., 2011), and as nuclear pro-
tein kinase (Gao et al., 2012; Jiang et al., 2014; Yang et al., 2012a)
were widely reported in the past few years. Although PKM2 pro-
tein kinase activity was questioned by a recent study (Hosios
et al., 2015), a more recent publication demonstrated that yeast
PKM2 can phosphorylate histone H3 both in vivo and in vitro (Li
et al., 2015b). Thus, it is possible that, while the protein kinase
activity of PKM2 may be low, due to the high abundance of
PKM2 in tumor cells, its protein kinase activity could still
contribute to the nuclear functions of PKM2 by regulating glycol-
ysis gene expression, Warburg effect, and tumor growth.
Nuclear PKM2 is activated following the stimulation of human
epidermal growth factor receptor (EGFR), while EGFR belongs to
a family of receptor tyrosine kinases (TKs) including EGFR,
ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) (Avraham
and Yarden, 2011). When binding to ligands such as EGF or
transforming growth factor, EGFR is activated and promotes
downstream events including cell proliferation and survival
(Hynes and Lane, 2005). EGFR is frequently overexpressed or
mutated in Glioma and lung cancers (Oxnard et al., 2011; Taylor
et al., 2012), but only few high-grade glioma show strong clinicalncer Cells
.5 mM), and cell proliferation was determined. Data are means ± SD (n = 3 in-
KM2 and PAR antibodies.
treated without or with olaparib and examined to determine the rate of cell
rmation assay. Viable colonies after 12 days were counted and analyzed (n = 4).
rib, and cell proliferation was measured at day 6 (n = 4).
rmation assay. Viable colonies after 12 days were counted and analyzed (n = 4).
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response to EGFR inhibitor like gefitinib (Taylor et al., 2012). This
is not due to the failure of this drug to cross blood-brain barrier
(Hegi et al., 2011), but due to the expression of extracellular-
domain EGFR mutant, EGFRvIII (Gan et al., 2009). On the other
hand, lung cancers also frequently express mutant EGFR. These
mutants of EGFR, commonly within EGFR kinase domain,
endow these lung cancers hypersensitive to EGFR inhibitors.
However, treatment with EGFR tyrosine kinase inhibitors in
lung cancer is not curative. These tumors often acquire second-
ary mutations within EGFR kinase domain (normally the T790M
mutation), which causes therapeutic resistance (Oxnard et al.,
2011). Therefore, new generations of EGFR inhibitors or combi-
natory therapies are being developed and tested to improve
treatment for lung cancer. The particularly interesting observa-
tion presented in our study is that PARP inhibitor treatment sup-
presses EGFR mutant tumor growth, including the EGFRvIII
mutant in glioblastoma (Figure 4) and EGFR-T790M mutant in
lung cancer cells (Figure 5). Moreover, combination of PARP in-
hibitor olaparib with EGFR inhibitor Gefitinib significantly over-
comes the acquired resistance in some lung cancer cells (Fig-
ures 5D and 5E). Our findings suggest that PARP inhibitors
may be used not only for the treatment of BRCA-deficient breast
cancer and ovarian cancer (Scott et al., 2015), but also for other
cancers that carry EGFRmutations and/or nuclear PKM2. Steer-
ing besides BRCA1/2, nuclear PKM2 can be used as a second-
ary biomarker for using in clinical treatment.
EXPERIMENTAL PROCEDURES
The information about antibody, constructs, cell culture, immunoprecipitation
and immunofluorescence, glutathione S-transferase (GST) pull-down and
mass spectrometry analysis, pyruvate kinase assay, glucose uptake assay,
lactate production assay, BrdU incorporation, laser microirradiation, surface
plasmon resonance, and in vitro PARsylation assay in this study is described
in Supplemental Experimental Procedures.
Dot-Blot Assay
GST fusion proteins (10 pmol) were conjugated to the glutathione beads and
incubated with Biotin-PAR (50 pmol, revigen) for 2 hr at 4C. The beads
were washed with 20mM Tris PH8.0, 100 mM NaCl, 1mM EDTA, 0.5% v/v
NP-40 buffer, and proteins from beads were eluted by glutathione and spotted
onto a nitrocellulose membrane. The membrane was blocked by Tris-buffered
saline containing Tween-20 (50mM Tris PH7.5, 150mMNaCl, 0.1% Tween-20)
buffer with 5% milk and was examined by anti-PAR antibody.
Cell Proliferation and Colony Formation Assays
For proliferation assay, equal numbers of cells were plated in 6-cm dishes.
From the next day, cells were collected and counted every day.
For colony formation assay, cells were seeded at 1,000 cells (for H1975
cells, seed 5,000 cells per dish) into 6-cm dishes. 12 hr after seeding, cells
were treated with olaparib (0.5 mM) or gefitinib (50 nM). Medium was replaced
every 2 days, and cells were incubated for 12 days. Resulting colonies were
fixed and stained with Coomassie blue. Numbers of colonies were counted
with a GelDoc with Quantity One software (Bio-Rad).Figure 6. Nuclear Localization of PKM2 Is Correlated with PAR Level i
(A) Immunohistochemical (IHC) staining of PKM2, PAR, and p-EGFR in glioblasto
microarrays. Brown staining indicates positive immunoreactivity. Scale bars, 50
(B) PAR, p-EGFR, and PKM2 expression status in glioblastoma and lung carcino
(C) IHC staining of p-EGFR, PAR, and PKM2 of representative human glioblastom
(D) Correlation between expression status of nuclear PKM2/p-EGFR and nuclea
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Human glioblastoma multiforme (GBM) tissue arrays and human lung cancer
tissue array (BC041115a) were purchased from US Biomax. GL805a and
GL806c all contain 35 cases of glioblastoma and five cases of normal cere-
brum. BC041115a contains 110 cases of lung carcinoma and ten cases of
normal lung tissue. Samples were deparaffinized and rehydrated, and antigens
were retrieved by using 0.01 M sodium-citrate buffer (pH 6.0) in a microwave
oven. To block endogenous peroxidase activity, the sections were treated
with 1% hydrogen peroxide in methanol for 30 min. After 1 hr pre-incubation
in 10% normal goat serum to prevent nonspecific staining, the samples
were incubatedwith antibodies to PAR (4335-MC-100, Trevigen, 1:50 dilution),
PKM2 (4053S, Cell Signaling Technology, 1:100 dilution), or EGFR-pY1172
(SAB400177, Sigma-Aldrich, 1:50 dilution) at 4C overnight. The sections
were then incubated with a biotinylated secondary antibody (Vector Labora-
tories, PK-6101, 1:200) for 3 hr and then incubated with avidin-biotin peroxi-
dase complex solution (1:100) for 30 min at room temperature. Color was
developed with the 3-amino-9-ethylcarbazole (AEC) solution. Sections were
counterstained with Mayer’s hematoxylin. All immunostained slides were
scanned on the Automated Cellular Image System III (ACIS III, Dako) for quan-
tification by digital image analysis. The correlation between proteins was
determined by chi-square analysis.
In Vivo Xenograft Study
All animal experiments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use Committee (IACUC) of
MD Anderson Cancer Center. Our experiments indicated that five or six
mice per group could identify the expected effect of PKM2 or olaparib on tu-
mor size and weight with 100% power. Animals were randomly assigned to
different groups. Tumor cells (5 3 106 in 100 ml of medium) were injected
into 6- to 8-week-old female BALB/c nude mice. Tumor size was measured
as indicated using a caliper, and tumor volume was calculated using the for-
mula 0.5 3 L 3 W2. Mice were euthanized when they met the institutional
euthanasia criteria for tumor size and overall health condition. The tumors
were removed, photographed, and weighed.
For olaparib-treated tumor study, we injected (5 3 106 in 100 ml of medium)
tumor cells into 6- to 8-week-old female BALB/c nude mice. After about
10 days, the tumor volume of sh-vector group reached a calculated average
volume of 65 mm3, and the tumor volume of all three groups was measured
(shv, shM2, and shM2+M2), and the animals in each group were randomized
into two sub-groups (five mice/sub-group): (1) vehicle control and (2) olaparib.
Mice were treated for 4 weeks, and olaparib was dosed (50 mg/kg i.p. injec-
tion) once daily for 5 days/week. Tumor volume was measured at indicated
days after treatment. Mice were euthanized and tumors were removed, photo-
graphed, and weighed 4 weeks after treatment.
Statistical Analysis
Each experiment was repeated there times or more, unless otherwise noticed.
No samples were from the excluded analysis, and samples were randomly as-
signed to different groups. Data were analyzed by the one-way ANOVA test
and Pearson chi-square analysis. We used an F-test to compare variances,
and the variances were not significantly different. A p value <0.05 was consid-
ered as statistically significant.
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